CTRI/2012/03/002531
Other
Phase 2
â??Double-blind, randomized study to evaluate the ability of H-009 and Arsenic-sulphuricum-flavum in stimulating pigmentation in vitiligo and examining safety in patientsâ?? - nil
Homeopathy India Private Limited0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Homeopathy India Private Limited
- Status
- Other
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with focal vitiligo. Focal vitiligo This type is characterized by one or more lesions in single area.
- •Patient is willing and able to give written informed consent
- •Vitiligo stable since 3 months, that is, there should have been no increase of spots in number or size, during last three months.
- •Patient having vitiligo spots, size up less than 15cm x 15cm.
Exclusion Criteria
- •Patient having extensive vitiligo, bilateral symmetrical or having onlymuco\-cutaneus junction (such as lips, genitals, finger\-tips, etc.) affection.
- •Any form of systemic, injectable or topical treatment (conventional, homeopathic, Ayurvedic, Cuben, Phototheraphy, surgical, laser, etc.) during the last 2 months
- •Patients having uncontrolled or untreated under active Thyroid. (To be ruled out by TSH study.)
- •Patient who are on or have consumed in last three months any anti\-cancer (conventional) medication.
- •Women of childbearing age who had tested positive for pregnancy, or who do not use acceptable contraceptive method, or do not agree to practice reliable contraception during the study.
- •Current Participation or participation in last 3 months period, in any clinical trial.
- •Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality, disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator may endanger the subject or interfere with the endpoints of study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 3
Management of chronic stable angina with an integrated approach of allopathic and ayurvedic medicationsHealth Condition 1: I998- Other disorder of circulatory systemCTRI/2023/06/054147Shathyu Ayurveda Pvt Ltd
Completed
Phase 3
A randomized, double-blind study to evaluate the safety and effectiveness of the Exhale Drug-eluting stent in homogeneous emphysema subjects with severe hyperinflation, the EASE - study. & Local ammendment: Protocol revision to evaluate the ExhaleUltraNeedle in the EASE study.COPDEmphysema10038716NL-OMON30701Broncus Technologies Inc.15
Active, Not Recruiting
Phase 1
Efficacy and Safety of apraglutide in steroid refractory gastrointestinal acute graft versus host diseaseAcute graft versus host disease (GVHD)MedDRA version: 20.0Level: PTClassification code 10075160Term: Graft versus host disease in gastrointestinal tractSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.0Level: LLTClassification code 10075161Term: Graft versus host disease in GI tractSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2021-004588-29-ESVectivBio AG34
Active, Not Recruiting
N/A
Double-blind, randomised trial to investigate the antihypertensive and metabolic effects of candesartan in insulin-resistant obese patients with a hypertension not adequately controlled by previous beta-blocker or calcium channel blockerEUCTR2006-001998-25-DETakeda Pharma GmbH
Active, Not Recruiting
N/A
A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathyeuropathic pain from lumbosacral radiculopathyMedDRA version: 12.0Level: LLTClassification code 10037779Term: RadiculopathyEUCTR2009-012836-33-DEGlaxoSmithKline Research & Development Limited142